Table 1.

Distribution characteristics of patients

	TB group (N=77)		Non-TB group (N=308)		P value for the absolute difference in IP
Variable	Total	No. Deaths (IP in %)1	Total	No. Deaths (IP in %)
Overall	77	11 (14.3)	308	21 (6.95)	0.071
Age
18–<30	27	5 (18.52)	113	4 (3.54)	0.026
30–<40	34	3 (8.82)	116	9 (7.76)	0.826
40–<50	13	3 (23.08)	63	7 (11.11)	0.359
50–70	3	0 (0.00)	10	1 (10.00)	0.786
Gender
Females	59	8 (13.56)	228	12 (5.26)	0.060
Males	18	3 (16.67)	74	9 (12.16)	0.652
Marital status
Married or cohabiting	28	4 (14.29)	110	9 (8.18)	0.396
Single	49	7 (14.29)	192	12 (6.25)	0.116
Source of referral
Any Muhimbili clinic	7	0 (0.00)	26	2 (7.69)	0.635
Infectious Diseases Centre	5	1 (20.00)	18	0 (0.00)	0.250
NGO VCT	39	7 (17.95)	157	10 (6.37)	0.061
Self referred	12	1 (8.33)	38	4 (10.53)	0.907
Other	14	2 (16.67)	63	5 (7.94)	0.523
CD4 count at or around the matching time
<200	49	7 (14.29)	191	11 (5.76)	0.090
200–<250	6	2 (33.33)	23	4 (17.39)	0.537
250–<300	7	0 (0.00)	28	4 (14.29)	0.437
300–<350	6	0 (0.00)	24	1 (4.17)	0.806
≥350–2000	9	2 (22.22)	36	1 (2.78)	0.137
On ART at matching
On medication	4	0 (0.00)	20	2 (10.00)	0.711
Not on medication	73	11 (15.07)	282	19 (6.74)	0.054
On ART at some point during follow-up
On medication	6	0 (0.00)	20	2 (10.00)	0.611
Not on medication	71	11 (15.49)	282	19 (6.74)	0.047
Vaccine arm
M. vaccae	28	7 (25.00)	146	9 (6.16)	0.016
Placebo	49	4 (8.16)	156	12 (7.69)	0.893
Isoniazid preventive therapy (at DarDar baseline)
Not eligible for therapy	50	6 (12.00)	214	15 (7.01)	0.303
Eligible, not adhered	7	4 (57.14)	10	2 (20.00)	0.335
Eligible, adhered	20	1 (5.00)	78	4 (5.13)	0.957
On co-trimoxazole at matching
On medication	38	6 (15.79)	78	5 (6.41)	0.173
Not on medication	39	5 (12.82)	224	16 (7.14)	0.296
On co-trimoxazole at some point during follow-up
On medication	68	10 (14.71)	135	8 (5.93)	0.073
Not on medication	9	1 (11.11)	167	13 (7.78)	0.705

¹IP stands for incidence proportion